All posts by imreal

What leads people to forfeit personal choice for economic security?


The character Faust signs his soul away to Mephistofle -- the devil -- in a painting by Eugène Siberdt

Faustian bargains occur when people trade moral value for material benefit, just as legend holds Faust did with the devil. New UofL research reveals factors that lead people to make that bargain.

(After 9/11) I noticed this instantaneous reaction where a society that values individual choice was very quick to be willing to give up some civil liberties to the government in the Patriot Act that called for increased surveillance. That is a fundamental Faustian bargain on steroids.

People value their right to make choices in life. However, in order to obtain important goods, services and protection, they are willing to give up some of that individual autonomy to government leaders, employers or others.

University of Louisville brain sciences researchers Daniel DeCaro and Marci DeCaro, who explore how people learn and make decisions, have published new research that reveals important factors that lead people who initially prefer personal choice to yield that authority to others. They found that people are more likely to yield decisions to others when they believe the others are more qualified to make choices that will prevent severe losses and increase economic benefit.

“It’s a fundamental aspect of human nature and society that we give up a little bit of our freedom of choice and authority in exchange for things we need for survival,” said Daniel DeCaro, associate professor in UofL’s Departments of Psychological and Brain Sciences and Urban and Public Affairs. “When you’re trying to weigh options, those options differ in terms of levels of freedom of choice and economic outcomes and security. This study helps us understand the actual trade-offs that might be happening in people’s minds and the mindset they get into when they’re making this kind of Faustian bargain.”

A Faustian bargain is when a person exchanges something of supreme moral value for a material benefit. The concept is based on the medieval legend of Faust, who traded his soul to the devil in return for knowledge and power. Daniel DeCaro is interested in understanding instances when an individual trades freedom of choice for economic benefit.

To understand at what point people are willing to make this exchange, the researchers developed a unique series of card selection tasks in which individuals can choose to make their own decisions or yield decisions to an individual they believe will choose more successfully. They recruited 77 young adults to participate in the study, which offered the opportunity for financial gain if they made correct choices. The participants could choose between two “managers” to work with them on the tasks: One manager allowed them to choose responses for themselves and the other instructed them in their choices.

When the card tasks were easy and the participants were successful, they were more likely to choose the choice-friendly manager and make selections for themselves. When the tasks were more difficult and their gains changed to losses, their preference shifted to the manager who chose better selections for them, even though the manager was coercive.

DeCaro said it is important for people to recognize this tradeoff when they are making important life or moral decisions such as employment, government leadership and public policy.

“It’s helpful for people to recognize when they’re in this type of situation and put a name on it so they can step back and think a little more carefully,” he said. “You’re explicitly trading off some sort of freedom for some economic exchange and it’s important to stop and decide if it is appropriate.”

DeCaro originally became interested in decision science as an undergraduate student around the time of the 9/11 terrorist attacks.

“I noticed this instantaneous reaction where a society that values individual choice was very quick to be willing to give up some civil liberties to the government in the Patriot Act that called for increased surveillance. That is a fundamental Faustian bargain on steroids,” he said. “Scholars are saying that we probably weren’t as careful as we should have been, because once you strike these Faustian bargains and they get codified in law and social norms, it becomes the new status quo. And then it’s very hard to change it.”

The study, “Formalizing the fundamental Faustian bargain: Inefficacious decision-makers sacrifice their freedom of choice to coercive leaders for economic security,” was published in the journal PLOS ONE. In addition to Daniel DeCaro, authors include Marci DeCaro and Rachel Appel of UofL and Jared Hotaling of the University of Illinois at Urbana-Champaign.

In designing the research, the investigators collaborated with Hotaling to develop an innovative cognitive model that combines two established concepts. Economic theory would predict that people always choose economic gain over loss. On the other hand, procedural justice theory says people most value freedom and always will prefer to choose for themselves. Neither theory accurately predicts how people make decisions in life, particularly in cases where the two values (freedom, economics) are pitted against one another, such as when exercising personal freedom carries the risk of economic loss. The cognitive model takes both concepts into account and tests the factors that lead a person to change their initial preference for freedom. They find that economic losses capture attention, causing individuals to focus on economic survival more than their own freedom.

In future research, the team plans to test how responses differ in different groups based on important factors that are known to affect attitudes toward personal and cultural authority and economic survivability, such as race, socioeconomic class and gender. They also plan to include individuals from diverse cultural backgrounds who would have different starting points in their preference for choice.

###

Painting: “Faust and Mephistofle” by Eugène Siberdt (1851-1931), public domain, via Wikimedia Commons.

Get more news from UofL delivered straight to your inbox by signing up for our UofL News Roundup here: uoflalumni.org/uoflnews-signup.

Share article on social media or email:

EVŌQ Bio Announces Participation in State of Utah Trade Delegation to Medica 2022 in Düsseldorf, Germany


“Our novel technology has been shown to radically reduce the onset of bacteria colonization and biofilm formation on inserted and implanted devices that can decrease the number of nosocomial infections.”- David Nilson, Vice President of EVŌQ Bio.

EVŌQ Bio (an EVŌQ Nano company), a nano-platform technology company, is pleased to announce their participation with the Utah Trade Delegation to Medica 2022 in Düsseldorf, Germany November 14 – 17, 2022. EVŌQ Bio specializes in the manufacturing of nano materials that can be extruded into and coat medical devices that are at risk of bacterial colonization and biofilm formation.

EVŌQ Bio has developed EVQ-218, a nanotherapeutic that shows broad spectrum activity against fungi, gram-negative and gram-positive bacteria without developing drug resistance. In vitro testing at Seattle Children’s Research Institute and animal studies at Lovelace Biomedical has confirmed efficacy against 60+ strains of multi-drug resistant bacteria while exhibited no toxicity at therapeutic doses. Third party minimum inhibitory concentration and biofilm inhibitory concentration testing demonstrated comparable or improved outcomes against leading antibiotics.

“Multi-drug resistant bacteria continue to have a significant impact in the healthcare setting,” said David Nilson, Vice President of EVŌQ Bio. “Our novel technology has been shown to radically reduce the onset of bacteria colonization and biofilm formation on inserted and implanted devices that can decrease the number of nosocomial infections. The broad-spectrum activity of our technology shows efficacy against staph, E. coli, pseudomonas, burkholderia and all NTM strains tested.”

In addition to medical devices, EVŌQ Bio’s poly-therapeutic platform leverages nano-technology in the development of antimicrobial applications including a pulmonary therapeutic to treat bacterial lung disease.

EVŌQ Bio’s attendance at Medica seeks to develop international partnerships to bring this technology to multiple device and supply manufacturers.

About EVŌQ Bio

EVŌQ Bio (an EVŌQ Nano, Inc company) is a nano-technology platform company developing early-stage pharmaceutical research and medical device applications to reduce the global threat of multi-drug resistant infections. Our technology and unique mechanism of action enables treatment and prevention of bacterial disease, without contributing to the growing list of drug-resistant pathogens.

Share article on social media or email:

Molecular Devices announces ValitaTiter IgG quantitation assay to fast track biologics sample testing


Using ValitaTiter with our SpectraMax microplate readers, SoftMax Pro Software, and automation solutions further enhances the reliability and reproducibility of assay results and enables seamless integration of the assay in regulated workflows.

Molecular Devices announced today the launch of the ValitaCell IgG titer assay, ValitaTiter, available for sale across North America and Europe. The new assay will complement Molecular Devices’ workflow solution for cell line development by offering a 10-minute titer assay that can be run on the company’s SpectraMax series of microplate readers.

Producing rapid results compared to HPLC, ELISA, and Biolayer Interferometry, ValitaTiter is the most efficient assay for minimizing cost and time to results because it works in the presence of cells, minimizes dilutions, eliminates wash steps, and easily integrates into automated high-throughput cell line development and process development workflows. Integrating ValitaTiter and Molecular Devices fluorescence polarization plate readers produce a seamless IgG titer assay setup and optimization process allowing teams to realize savings on time and resources as well as faster time-to-market.

Molecular Devices’ technical support team and PhD-level field application scientists partner with their customers to create complete automated workflows to shorten the time to market for critical vaccines and therapeutics. This workflow will now include the ValitaTiter IgG assay. Molecular Devices’ long history of developing regulatory compliance solutions and software will ensure a streamlined regulatory and validation process.

“Integrating ValitaTiter gives us a great opportunity to expand our cell line development workflow even further, to bring therapeutics to market faster,” said Terrell Mathews, Vice ​President of Global Sales at Molecular Devices. “Using ValitaTiter with our SpectraMax microplate readers, SoftMax Pro Software, and automation solutions further enhances the reliability and reproducibility of assay results and enables seamless integration of the assay in regulated workflows.”

Learn more about the ValitaTiter IgG quantitation assay from Molecular Devices here.

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software, and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continuous development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

About ValitaCell

ValitaCell’s mission is to accelerate the pace and reduce the cost of manufacturing innovative medicines. We are focused on enabling our biopharmaceutical customers to bring medicines to the patients that need them most, in the shortest length of time. Most drugs that advance to clinical trial fail before they make it to the market. This failure increases costs and delays lifesaving treatments for patients. Our team is focused on creating analytical technologies that empower scientists with rich cell data and insights earlier in the drug discovery and development process. We are committed to advancing human healthcare worldwide. In September 2022, ValitaCell was acquired by Beckman Coulter Life Sciences.

Valita and Valita Titer are trademarks of ValitaCell.

SpectraMax and SoftMax are trademarks of Molecular Devices, LLC.

Share article on social media or email:

ColoWrap Curtails Endoscopists’ Ergonomic Risk in Large Study, Enables Completion of Prior Failed Colonoscopy Resulting in Cancer Detection — Data Presented at ACG 2022


ColoWrap Anti-Looping Colonoscopy Compression Device

ColoWrap Anti-Looping Colonoscopy Compression Device

“Particularly for challenging cases, technology like ColoWrap that can help minimize looping and associated ergonomic risks offers a major return on investment.”

ColoWrap, LLC., the pioneer in the development of external compression technology to facilitate endoscopic procedures, today announced that two abstracts demonstrating how the Company’s products minimize ergonomic risks and enhance patient outcomes were selected for presentation during the American College of Gastroenterology (ACG) 2022 Annual Meeting, held October 16-21 in Charlotte, NC.


  • In an 849-patient study, 2 in 3 physicians using the ColoWrap Anti-Looping Compression Device reported significant to very significant reductions in physical strain while performing colonoscopy. Torquing of the scope due to looping is a significant risk factor for musculoskeletal injury among endoscopists; nearly 20% of endoscopists reduce procedure volume due to overuse injuries, costing hospitals millions and reducing patient access to screening colonoscopy.


“That physicians experienced less strain while performing colonoscopy is a meaningful endpoint. Improving the ergonomics of colonoscopy for the physician could reduce the risk of injury,” said study author Seth Gross, MD, Chief of Gastroenterology at NYU Langone Medical Center. “Particularly for challenging cases, technology like ColoWrap that can help minimize looping and associated ergonomic risks offers a major return on investment.”

ColoWrap also decreased the need for staff-applied manual abdominal pressure and patient repositioning by 80% compared to published rates. These two physically demanding techniques are a significant risk factor for musculoskeletal injuries in nurses and technicians that perform them.

  • In a case study presented by Dr. Dean Edwards (Gastroenterology Associates of Southeast MO), ColoWrap use enabled successful cecal intubation in a patient with a previous incomplete colonoscopy who had a known lesion detected by imaging in the proximal colon. ColoWrap’s intra-procedure adjustability was highlighted as critical to overcoming the anatomical difficulties, including obesity and abdominal adhesions resulting from a prior gunshot wound, that had resulted in the failure of the prior exam. Successful completion of the colonoscopy with ColoWrap enabled detection of an early-stage tumor which the patient subsequently had removed.

Tony Kalloo, MD, Chair of Medicine at Maimonides Medical Center, and Head of ColoWrap’s Clinical Advisory Board shared his enthusiasm for the continued validation of the Company’s founding principal.

“From the word go I’ve believed in the concept of using external, non-manual force to help facilitate endoscopic procedures. Now we’re seeing this vision start to come to life and generate real results and it’s thrilling. This is only the start for how far the technology can be leveraged.”

About ColoWrap, LLC.

ColoWrap® is an early-stage medical company and the pioneer of external compression technology to facilitate endoscopy. The Company’s flagship product, the ColoWrap Anti-Looping Colonoscopy Compression Device is the first and only non-invasive device that has been clinically proven to mitigate looping during colonoscopy. Worn by the patient during the exam, the device applies targeted, adjustable abdominal pressure to minimize sigmoid and transverse looping. In clinical trials, ColoWrap has been shown to shorten procedure time, improve patient comfort, and reduce staff-reported musculoskeletal pain by 85%. Learn more at https://www.colowrap.com

Follow ColoWrap on LinkedIn, Twitter, Facebook, and Instagram.

Share article on social media or email:



MADD Survey Reveals Need to Encourage Parents to Talk to Kids About the Dangers of Alcohol and Other Drugs More Frequently


News Image

Studies show that when parents allow their high schoolers to have a small glass of wine or a beer on ‘special occasions,’ the teens are likely to drink more often and in greater amounts when they are not with their parents.

The COVID-19 pandemic has undoubtedly touched each American family, with massive disruptions to work, school, and social routines. Now entering the third year of the pandemic – with many facets of American life returning to normal – Mothers Against Drunk Driving® (MADD) sought to check in with U.S. parents and their teens on topics like alcohol and cannabis consumption, binge drinking, and substance impaired driving through a recent survey. Survey results revealed the need for conversations between parents and teens about the dangers of alcohol and other drugs.

In February 2022, MADD commissioned IPSOS, a global research company, to conduct a nationwide study — a random sample of approximately 1,000 parents and their high school teens ages 15-18.

The survey found parents may be devaluing their role in preventing underage drinking – both their influence on teens’ decision-making and their ability to curb access to alcohol at home – because this topic is not being discussed enough. In fact, of the parents surveyed, half report discussing the potential consequences with their high school teen just one to three times in the past year (39%) or not at all (12%). By contrast, relatively few (13%) are tackling the subject 12 or more times a year, as is recommended by Dr. Turrisi in MADD’s Power of Parents handbook.

The most alarming of the results reveal that a third of parents allow youth access to alcohol according to both teen and parent responses. Of the parents surveyed, one in five (21%) say they allow alcohol consumption from time to time, while a smaller amount (9%) allow it fairly often. About two-thirds (64%) of teens say their parents have not allowed them to consume alcohol, with more having discussed the subject with their parents (36%) versus saying it has not come up (28%). The remainder of teens say their parents have allowed them to consume alcohol – mostly with them (29%) as opposed to without them (8%).

Additional key findings of the report include:

  • Teens are less likely to characterize certain behaviors as high risk opposed to parent views on binge drinking and mixing alcohol and marijuana (each six percentage points lower among teens).
  • There are large differences between mothers and fathers on perceptions of risk and strong disapproval of behaviors surveyed, with mothers taking a more cautious stance. This gender divide is seen among teen girls vs. boys, as well.

“In addition to talking to their teenagers, it’s equally important for parents to set the example by not allowing underage drinking in their home,” said Alex Otte, MADD National President. “Studies show that when parents allow their high schoolers to have a small glass of wine or a beer on ‘special occasions,’ the teens are likely to drink more often and in greater amounts when they are not with their parents.”

According to the Centers for Disease Control and Prevention (CDC), excessive drinking is responsible for more than 4,300 deaths among underage youth each year and can lead to early addiction as well as many other dangerous outcomes, including drunk driving. MADD’s Power of Parents program is focused on empowering parents of middle school and high school students to have ongoing, intentional conversations about the dangers and consequences of underage drinking and drug use to combat these statistics. Parents can download free Power of Parents handbooks at http://www.madd.org/powerofparents.

“MADD thanks General Motors for their support in funding this important project. We are so grateful for their dedication to our shared mission to stop these tragedies that destroy families and devastate our communities,” Otte said.

“General Motors is proud to have supported MADD as they conducted this research,” said Terry Rhadigan, vice president of Corporate Giving at GM. “We believe the findings in the report will spark important conversations between parents and their children, which will help reduce the occurrence of impaired driving and other unsafe behavior.”

To review the survey results, visit madd.org/reports.

About Mothers Against Drunk Driving

Founded in 1980 by a mother whose daughter was killed by a drunk driver, Mothers Against Drunk Driving® (MADD) is the nation’s largest nonprofit working to end drunk driving, help fight drugged driving, support the victims of these violent crimes and prevent underage drinking. MADD has helped to save more than 400,000 lives, reduce drunk driving deaths by more than 50 percent and promote designating a non-drinking driver. MADD’s Campaign to Eliminate Drunk Driving® calls for law enforcement support, ignition interlocks for all offenders and advanced vehicle technology. MADD has provided supportive services to nearly one million drunk and drugged driving victims and survivors at no charge through local victim advocates and the 24-Hour Victim Help Line 1-877-MADD-HELP. Visit http://www.madd.org or call 1-877-ASK-MADD.

About General Motors

General Motors (NYSE:GM) is a global company focused on advancing an all-electric future that is inclusive and accessible to all. At the heart of this strategy is the Ultium battery platform, which will power everything from mass-market to high-performance vehicles. General Motors, its subsidiaries and its joint venture entities sell vehicles under the Chevrolet, Buick, GMC, Cadillac, Baojun and Wuling brands. More information on the company and its subsidiaries, including OnStar, a global leader in vehicle safety and security services, can be found at https://www.gm.com.

Share article on social media or email:

Antidote Technologies and Beyond Celiac to Match Celiac Patients with Research Opportunities


Beyond Celiac and Antidote are collaborating to drive celiac disease research forward.

“Partnering with Antidote will help the celiac patient community find and connect to clinical trials in an easy and patient-friendly way.” – Maria Luci, Director of Research Engagement at Beyond Celiac

Antidote Technologies (Antidote), a patient-centric digital engagement company focused on connecting patients with clinical research, today announced a collaboration with Beyond Celiac, the leading celiac disease organization working to drive diagnosis, advance research, and accelerate the discovery of new treatments and a cure. The collaboration leverages Antidote’s best-in-class clinical trial search technology with Beyond Celiac’s deep understanding of the condition and the motivation of patients living with celiac to participate in medical research. Ultimately, the goal of both organizations is to offer a patient-friendly journey that leads to better quality clinical trial search results.

Living with celiac disease can be difficult. It causes uncomfortable symptoms, impacts food choices, and creates anxiety in food settings. And, it can lead to damage to the small intestine’s lining and impact the body’s ability to absorb certain nutrients. That’s why for the 1 in 133 Americans who live with celiac disease, new and better treatment options are critical.[1] There are more than 45 celiac disease clinical trials currently looking for such treatment options. But to fully enroll these studies, more than 245,000 patients would need to take part.[2]

“Living with celiac disease is a challenge faced by so many, but we believe research can change that,” said Maria Luci, Director of Research Engagement at Beyond Celiac. “We’re confident that better treatments are in our future, but patients need to take part in clinical trials in order to make that happen. Partnering with Antidote will help the celiac patient community find and connect to clinical trials in an easy and patient-friendly way.”

For a long time, treatment for celiac disease focused on adopting and maintaining a gluten-free diet, but this comes with many challenges. Now, there are a variety of therapeutic approaches being studied, including breaking down gluten using enzymes, interrupting the effects of gluten on the cells lining the intestine, preventing the enzyme tTG from modifying gluten in the cell, inducing immune tolerance, and interrupting the immune reactions that occur.[3] Patients can match to these and more trials through the new search on the Beyond Celiac website powered by Antidote.

“We see the great unmet need in the celiac disease community, and we’re honored to provide a custom search through Beyond Celiac,” said Laurent Schockmel, CEO of Antidote. “We’re grateful to Beyond Celiac for collaborating so closely with us to offer a superior clinical trial search experience for patients and caregivers affected by celiac disease.”

To search for a celiac disease trial, visit the Beyond Celiac website. If you’re interested in learning how you can offer patient-friendly clinical trial search on your website, please get in touch today.

About Antidote

Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.

About Beyond Celiac

Since 2003, Beyond Celiac has been the leading patient advocate and research-driven celiac disease organization working to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. By engaging with the top scientists in the field, awarding research grants, and supporting the community, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives and eat without fear – a world Beyond Celiac.

Media contacts

Lisa Conroy, Head of Communications

Antidote

lisa@antidote.me

215-872-2917

Grace McElroy, VP of Patient Experience & Partnerships

Antidote

grace@antidote.me

914-643-5260

Claire Baker, Senior Communications Director

Beyond Celiac

cbaker@BeyondCeliac.org

267-419-2111

References

[1] https://www.beyondceliac.org/celiac-disease/facts-and-figures

[2] https://www.clinicaltrials.gov/ct2/results?cond=celiac&term=&cntry=&state=&city=&dist=&recrs=a

[3] https://www.beyondceliac.org/research/drugdevelopment/drug-development-pipeline/

Share article on social media or email:

Ventura’s Leading Cosmetic Dentist, Dr. Saj Jivraj Recognized as a Winner of 2022 Readers’ Choice Award for Dental Implants.


Award

Award

Let Us Exceed Your Expectations

WHY CHOOSE THE SPECIALISTS AT ANACAPA DENTAL ART INSTITUTE?

Today many dental practices advertise the “Teeth in a day” or the “All on 4™ concepts. Essentially the concept involves removal of all of a patient’s teeth when indicated, placement of 4 dental implants per jaw and placement of permanent teeth the same day. These teeth are temporary teeth which are made of plastic which the patient wears for 4-6 months after which definitive teeth are made.This concept advocates bone removal to find sufficient bone and to avoid bone grafting procedures. When this bone is removed gum is also lost and the patient ends up having artificial pink gum which replaces the bone and the gum. This concept is indicated for a specific clinical situation and should not be done for everyone that has all their teeth missing.

At Anacapa Dental Art Institute our philosophy is different and we espouse to the following protocols.

1. MORE THAN 4 DENTAL IMPLANTS

When possible, we place more than 4 implants per jaw just in case one implant does not take. You can imagine if you have four implants, and one implant fails the teeth cannot stay on three implants. It’s like a table having four legs and one leg being damaged. That table would not longer stand. We make decisions based on the patients’ needs and not on a specific treatment method. If we need to place more than 4 implants, we do that. From a patient’s perspective they think it will COST MORE. At Anacapa Dental whether we place 4 or 6 implants the cost stays the same. The additional implants provide the patient with added security.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point1.jpg

2. MINIMAL BONE REMOVAL

The traditional all on 4™ concept involves bone removal, placement of 4 implants and teeth the same day. The improved protocols involve preserving bone and gum and over engineering by placing additional implants when bone is available with the philosophy of keeping the surgical costs the same. We have a MINIMALLY INVASIVE technique where we preserve your own bone rather than remove it. In this way you maintain your own gum.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point2.jpg

3. NO IMPRESSIONS – TECHNOLOGY

Patients often come in with loose teeth and are frightened of having impressions made as they feel their teeth will come out with the impression. At Anacapa Dental we have Intra-oral scanners which are essentially tiny video cameras and we scan your teeth without touching them and 3D print models.

https://youtu.be/NgsBtjx8H70

4. HIGH END TECHNOLOGY, CT SCANS, FACE SCANNERS, 3D PRINTERS

We take 3D patient imaging via CT scans so we have all the information we need prior to surgery. WE have the CT scan on site and patients do not have to travel to another facility.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point4.jpg

5. ACCURATE IMPLANT PLACEMENT

We utilise technology which combines information from the CT scan and the Intra-oral scanner to fabricate a 3D surgical guide which is used to place dental implants. This allows precise positioning and optimal outcomes. We use high end implants that are backed by research.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point5.jpg

6. TEETH THE SAME DAY

You will get beautiful teeth the same day of surgery that do not move around and are not removable. These teeth are temporary but will have amazing aesthetics. You will wear these teeth for 4-6 months after which new ZIRCONIA based teeth will be fabricated.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point6.jpg

7. ALL SPECIALISTS IN ONE SITE – REVISION TREATMENT

No longer do you have to travel from office to office to have your teeth taken care of. We have surgical specialists, anaesthesiologists, Prosthodontists and Master Dental technicians on site. Every Doctor working on you is very experienced and is a specialist. Our specialists have written books, articles and teach this procedure to dentists around the world. You can be sure they have completed treatment on thousands of patients. You can feel comfortable that you will be in very experienced hands. 65% of our work involves re-doing what others have done. We get referrals from dentists around the globe to take care of their patients.

8. ON SITE DENTAL LAB

We have an on-site dental lab. This lab has state of the art technology and more importantly Master Dental Technicians who are extremely qualified to deliver the highest level of cosmetics. The final teeth are made of ZIRCONIA. They are strong, don’t stain, smooth and are very well accepted by the mouth biologically.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point8.jpg

9. WARRANTY

This is a significant investment. We understand that and we provide you a peace of mind warranty. The implants are warranted for 5 years and the teeth for 10 years. This warranty is based on two things 1. Returning regularly for dental cleanings, we have to help you maintain the implants 2. At the end of treatment, we will provide you with a night-guard. It is very important you wear this to prevent damaging your teeth at night when most people grind their teeth. WE WANT YOUR TEETH TO LAST.

10. AN AMAZING TEAM

We have a very experienced team that will take care of you all the way. We endeavour to EXCEED YOUR EXPECTATIONS.

https://www.dentalimplantsventura.com/wp-content/uploads/2022/10/Point10.jpg

Patients often come to us looking for a second opinion or consultation. When you go to several consultations you will understand that not every place is the same. This is a significant investment wherever you go. You must be sure you have chosen the right place for your care as this is a very important decision.

At Anacapa Dental we understand that and will provide you with all the information you need so you can make the best decision for yourself

Please look through the rest of our website for more information and patient testimonials. These patients have been through what you are contemplating and will give you comfort in making the right decision.

For a consultation, please call tel:+18059883317 [805-988-8985]

We look forward to meeting you and EXCEEDING YOUR EXPECTATIONS.

The Team at Anacapa Dental Art Institute.

Share article on social media or email:

Vyne Dental Achieves Full Accreditation From the Healthcare Network Accreditation Program


News Image

“With this important accreditation, Vyne Dental will continue to drive the dental industry by providing innovative solutions to improve workflow, decrease administrative costs and improve reimbursements,” says Vance Taylor, Chief Growth Officer at Vyne.

A leader in healthcare and service-provider technology, Vyne DentalⓇ announced today it has achieved full accreditation with the Healthcare Network Accreditation Program (HNAP) for Electronic Health Networks (EHN) from the Electronic Healthcare Network Accreditation Commission (EHNAC). EHNAC is a voluntary, self-governing standards development organization established to develop standard criteria and accredit organizations that electronically exchange healthcare data. HNAP EHN accreditation recognizes excellence in health data processing and transactions and is intended for organizations whose electronic health networks perform claims clearinghouse or EDI gateway functions to ensure compliance with industry-established standards and HIPAA regulations. Through EHNAC’s comprehensive third-party review, Vyne Dental was evaluated in areas of privacy measures, systems availability, and security infrastructure. In addition, EHNAC reviewed the organization’s process of managing and transferring protected health information and determined that the organization meets or exceeds all EHNAC criteria and industry standards.

Vyne Dental strategically develops solutions for dental practices, healthcare providers, and insurance plans and payers that facilitate the secure exchange of health information in a digital, end-to-end revenue cycle, optimizing cash flow while reducing associative costs. By being formally accepted as an EHNAC HNAP-EHN accredited organization, this notable achievement certifies that Vyne Dental’s quality products and services are held to a superior standard. Through the completion of the rigorous accreditation process, Vyne Dental demonstrates adherence to strict standards and participation in the comprehensive, objective evaluation of its business. Attaining this ‘seal of approval’ demonstrates Vyne Dental’s full commitment to ensuring the security and privacy of health data processing and transactions for their customers.

“With this important accreditation, Vyne Dental will continue to drive the dental industry by providing innovative solutions to improve workflow, decrease administrative costs and improve reimbursements,” says Vance Taylor, Chief Growth Officer at Vyne.

More about Vyne Dental:

Vyne Dental helps clients manage their revenue cycle, send encrypted communications and position their practices to thrive. Vyne Dental’s solutions deliver greater operational efficiency, financial performance, and improved data protection to more than 74,000 dental practice offices across the U.S. The company also partners with more than 800 dental plans and payers for the electronic delivery of claim documentation. For more information, please visit http://www.vynedental.com.

© 2022 Napa EA/MEDX, LLC. All rights reserved. All third-party trademarks and tradenames (including logos and icons) referenced are and remain the property of their respective owners.

A leader in healthcare and service-provider technology, Vyne DentalⓇ announced today it has achieved full accreditation with the Healthcare Network Accreditation Program (HNAP) for Electronic Health Networks (EHN) from the Electronic Healthcare Network Accreditation Commission (EHNAC). EHNAC is a voluntary, self-governing standards development organization established to develop standard criteria and accredit organizations that electronically exchange healthcare data. HNAP EHN accreditation recognizes excellence in health data processing and transactions and is intended for organizations whose electronic health networks perform claims clearinghouse or EDI gateway functions to ensure compliance with industry-established standards and HIPAA regulations. Through EHNAC’s comprehensive third-party review, Vyne Dental was evaluated in areas of privacy measures, systems availability, and security infrastructure. In addition, EHNAC reviewed the organization’s process of managing and transferring protected health information and determined that the organization meets or exceeds all EHNAC criteria and industry standards.

Vyne Dental strategically develops solutions for dental practices, healthcare providers, and insurance plans and payers that facilitate the secure exchange of health information in a digital, end-to-end revenue cycle, optimizing cash flow while reducing associative costs. By being formally accepted as an EHNAC HNAP-EHN accredited organization, this notable achievement certifies that Vyne Dental’s quality products and services are held to a superior standard. Through the completion of the rigorous accreditation process, Vyne Dental demonstrates adherence to strict standards and participation in the comprehensive, objective evaluation of its business. Attaining this ‘seal of approval’ demonstrates Vyne Dental’s full commitment to ensuring the security and privacy of health data processing and transactions for their customers.

“With this important accreditation, Vyne Dental will continue to drive the dental industry by providing innovative solutions to improve workflow, decrease administrative costs and improve reimbursements,” says Vance Taylor, Chief Growth Officer at Vyne.

More about Vyne Dental:

Vyne Dental helps clients manage their revenue cycle, send encrypted communications and position their practices to thrive. Vyne Dental’s solutions deliver greater operational efficiency, financial performance, and improved data protection to more than 74,000 dental practice offices across the U.S. The company also partners with more than 800 dental plans and payers for the electronic delivery of claim documentation. For more information, please visit http://www.vynedental.com.

© 2022 Napa EA/MEDX, LLC. All rights reserved. All third-party trademarks and tradenames (including logos and icons) referenced are and remain the property of their respective owners.

Share article on social media or email:

ScriptDrop and Redi.Health Partner to Improve Long-Term Health Outcomes


News Image

Both leadership teams include alumni of CoverMyMeds, and also share a mission of helping patients remain adherent to their prescriptions, while improving their long-term health outcomes.

Today, ScriptDrop Inc., a healthcare technology company focused on nationwide prescription access, and Redi.Health, provider of the leading health management technology that puts patient support in your pocket, are announcing a strategic partnership that improves patient access to information and provides tools that help them manage their prescriptions, and thus, their quality of life.

“Both leadership teams include alumni of CoverMyMeds, and also share a mission of helping patients remain adherent to their prescriptions, while improving their long-term health outcomes,” said Amanda Epp, CEO of ScriptDrop. “We fill in different gaps in the patient experience, so together, we’re really completing the circuit of healthcare.”

With this partnership, Redi.Health and ScriptDrop are delivering a streamlined solution for patients, providers, pharmacists, PBMs, and pharmaceutical manufacturers to better understand and manage medications. The joint offering combines ScriptDrop’s home prescription delivery solution with Redi.Health’s platform of medication reminders, symptom trackers, manufacturer support and more. This pairing will ensure patients have dependable access to prescriptions and can improve their health outcomes, while also helping build trust between patients and pharmaceutical manufacturers.

A new study shows that ScriptDrop delivery recipients who seamlessly transition into Redi.Health’s digital health management are 4x more likely to use adherence support services, and 72% of patients who use ScriptDrop delivery continue regularly receiving their medication. As Redi.Health and ScriptDrop continue to work together, these numbers will undoubtedly increase.

“We understand the vital role medication management plays in quality of life for patients, and so providing digital support for delivery plus access to information about these medications is a game-changer for patients and the healthcare industry alike,” said Luke Buchanan, co-founder and CEO of Redi.Health. ”As Columbus, Ohio-based companies, Redi.Health and ScriptDrop are aligned in many ways, but at the core is our focus on helping deliver a patient-centric approach that results in better outcomes for everyone.”

In an effort to accelerate the development of innovative drug therapies, Redi.Health and ScriptDrop are already looking ahead to shared clinical trials. With ScriptDrop’s nationwide presence and a user base that spans many demographics, this partnership will also help support the identification and recruitment of eligible and highly diverse patients, including those in rural areas.

About ScriptDrop

ScriptDrop is the only healthcare IT company specializing in prescription access that serves patients in all 50 states. Since 2017, ScriptDrop has been improving drug adherence by delivering medication access opportunities through a robust platform, long-term data storage, multiple service levels, and first-class customer service.

For more information, go to scriptdrop.co.

Media Contact:

Jessi Behrendsen

ScriptDrop

jessi@scriptdrop.co

About Redi.Health

Redi.Health empowers patients with chronic conditions to understand, manage and track their total health through digital support. Combining health management technology and pharmaceutical manufacturer support into one tool, Redi.Health provides a mobile platform that allows patients to manage everything from multiple medications and symptoms to diet and exercise. By delivering a pathway for pharmaceutical companies, providers and patients to connect and engage, Redi.Health customizes the complete health journey to drive better health outcomes.

Share article on social media or email:

UNA impacts billion-dollar staffing company, revolutionizing candidate readiness


News Image

“We focus on removing barriers to compliance testing, and we’re proud to show that doing so improves competency testing completion rates without compromising on quality.”

UNA Health Inc., a leading provider of mobile recruitment, onboarding, and testing solutions for healthcare staffing companies and hospitals, is excited to announce study results that showed a 33% improvement in competency testing completion rates compared to hospital learning management system, Relias. After switching to UNA’s mobile competency testing platform, a top ten national healthcare staffing agency immediately realized a significant increase in the volume of their qualified applicant pool.

The study compared competency assessment completion data, from the two leading assessment providers in the healthcare staffing industry. Completion data is critical because it speaks to candidates who are fully credentialed/compliant, and prepared to be placed on assignment. A candidate who cannot complete a competency exam, as part of their requirements to work, is unable to be employed.

By gathering metrics from a national staffing company that generated over $1B in revenue in 2021, the study showed that factors such as improved speed to completion and a frictionless digital experience led to a direct improvement in the number of candidates who are “ready to work.”

“Our approach has always been to place the user front and center,” said Ron Gonzalez, CEO of UNA Health, Inc. “We focus on removing barriers to compliance testing, and we’re proud to show that doing so improves competency testing completion rates without compromising on quality. We make it faster and easier for healthcare professionals to go through applicant screening, and that directly correlates to ROI for our staffing partners.”

The mobile experience and intuitive design in the UNA platform is the key differentiator to other testing providers. It offers flexibility without compromising capability to on-the-go healthcare professionals, providing time savings, and rapidly improving top-line revenue for staffing companies. Moreover, it produces secondary benefits through productivity savings for recruitment and credentialing teams by minimizing time spent on unqualified candidates. UNA’s platform is a clear improvement over Relias.

“Today’s healthcare talent is mobile first, they’re used to seamless user experiences, and they expect compliance testing to work for them,” says Bob Livonius, Staffing Industry Expert, Executive, and UNA Board Member. “UNA Test meets them where they are, helps them to full compliance, and launches them into the workforce faster than any other competency testing compliance solution.”

To read the full case study, visit https://www.unahealth.co/casestudy/.

About UNA Health:

UNA is an innovative mobile technology company creating solutions to solve onboarding, recruitment, and compliance challenges, including better ways for hospitals and healthcare employment firms to connect candidates to opportunities, improving applicant engagement, facilitating compliance workflows and establishing baseline clinical competencies.

Share article on social media or email: